PURPOSE: To identify the determinants of antibody responses to adjuvanted influenza A/H1N1/09 vaccines in a cohort of cancer outpatients. PATIENTS AND METHODS: Patients with cancer and controls were enrolled in a prospective single-center field study. Two doses of AS03-adjuvanted pandemic influenza vaccine were administered to patients and one dose was administered to controls. Antibody responses were measured using hemagglutination inhibition and confirmed by microneutralization. Geometric mean titers (GMTs) and seroprotection rates (defined as GMTs ≥40) were compared. RESULTS: Immunizations were safe and well tolerated in 197 cancer patients (lymphoma, 57; glioma, 26; lung or head and neck, 37; gastrointestinal, 41; breast, 36) and 138 controls. Similar seroprotection rates (82.3% versus 87%) and GMTs (336.9 versus 329.9) were achieved after two doses of adjuvanted vaccine in cancer patients and one dose in controls. Univariate analyses identified older age, prior immunization against seasonal influenza, lymphoma, CD4 count, active chemotherapy, and rituximab and steroid treatments as being associated with weaker antibody responses. However, only age and chemotherapy plus rituximab remained independent determinants of vaccine responses in multivariate analyses. CONCLUSIONS: Two doses of AS03-adjuvanted influenza vaccine elicited potent antibody responses in most cancer patients despite ongoing chemotherapy, with the exception of rituximab-induced B-cell depletion. Oncology patients treated in an outpatient setting benefit from preventive vaccination against influenza with adjuvanted vaccines.
PURPOSE: To identify the determinants of antibody responses to adjuvanted influenza A/H1N1/09 vaccines in a cohort of cancer outpatients. PATIENTS AND METHODS: Patients with cancer and controls were enrolled in a prospective single-center field study. Two doses of AS03-adjuvanted pandemic influenza vaccine were administered to patients and one dose was administered to controls. Antibody responses were measured using hemagglutination inhibition and confirmed by microneutralization. Geometric mean titers (GMTs) and seroprotection rates (defined as GMTs ≥40) were compared. RESULTS: Immunizations were safe and well tolerated in 197 cancerpatients (lymphoma, 57; glioma, 26; lung or head and neck, 37; gastrointestinal, 41; breast, 36) and 138 controls. Similar seroprotection rates (82.3% versus 87%) and GMTs (336.9 versus 329.9) were achieved after two doses of adjuvanted vaccine in cancerpatients and one dose in controls. Univariate analyses identified older age, prior immunization against seasonal influenza, lymphoma, CD4 count, active chemotherapy, and rituximab and steroid treatments as being associated with weaker antibody responses. However, only age and chemotherapy plus rituximab remained independent determinants of vaccine responses in multivariate analyses. CONCLUSIONS: Two doses of AS03-adjuvanted influenza vaccine elicited potent antibody responses in most cancerpatients despite ongoing chemotherapy, with the exception of rituximab-induced B-cell depletion. Oncology patients treated in an outpatient setting benefit from preventive vaccination against influenza with adjuvanted vaccines.
Authors: Ramesh K Ramanathan; Douglas M Potter; Chandra P Belani; Samuel A Jacobs; Stefan Gravenstein; Felix Lim; Hyoung Kim; Steven Savona; Terry Evans; Dianne Buchbarker; Mary B Simon; Jane K Depee; Donald L Trump Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: B Rousseau; P Loulergue; O Mir; A Krivine; S Kotti; E Viel; T Simon; A de Gramont; F Goldwasser; O Launay; C Tournigand Journal: Ann Oncol Date: 2011-05-16 Impact factor: 32.976
Authors: Tone Nordøy; Ingeborg S Aaberge; Anne Husebekk; Helvi H Samdal; Svein Steinert; Hasse Melby; Arne Kolstad Journal: Med Oncol Date: 2002 Impact factor: 3.064
Authors: Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold Journal: Blood Date: 2013-07-12 Impact factor: 22.113
Authors: Roy E Strowd; Katrina Swett; Michele Harmon; Annette F Carter; Aurora Pop-Vicas; Michael Chan; Stephen B Tatter; Thomas Ellis; Maria Blevins; Kevin High; Glenn J Lesser Journal: Neuro Oncol Date: 2014-04-08 Impact factor: 12.300
Authors: P Pedrazzoli; F Baldanti; I Donatelli; M R Castrucci; F Puglisi; N Silvestris; S Cinieri Journal: Ann Oncol Date: 2014-03-11 Impact factor: 32.976
Authors: Peter Vink; Ignacio Delgado Mingorance; Constanza Maximiano Alonso; Belen Rubio-Viqueira; Kyung Hae Jung; Juan Francisco Rodriguez Moreno; Enrique Grande; David Marrupe Gonzalez; Sarah Lowndes; Javier Puente; Hartmut Kristeleit; David Farrugia; Shelly A McNeil; Laura Campora; Emmanuel Di Paolo; Mohamed El Idrissi; Olivier Godeaux; Marta López-Fauqued; Bruno Salaun; Thomas C Heineman; Lidia Oostvogels Journal: Cancer Date: 2019-02-01 Impact factor: 6.860